MIEF2

Summary

MIEF2 (mitochondrial elongation factor 2, HGNC:17920) is a protein-coding gene on chromosome 17p11.2, encoding Mitochondrial dynamics protein MID49 (Q96C03). Mitochondrial outer membrane protein involved in the regulation of mitochondrial organization.

This gene encodes an outer mitochondrial membrane protein that functions in the regulation of mitochondrial morphology. It can directly recruit the fission mediator dynamin-related protein 1 (Drp1) to the mitochondrial surface. The gene is located within the Smith-Magenis syndrome region on chromosome 17. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 125170 — RefSeq curated summary.

At a glance

• Gene–disease (curated): mitochondrial disease (Limited, ClinGen) — +1 more curated relationship
• GWAS associations: 1
• Clinical variants (ClinVar): 130 total — 3 pathogenic
• Phenotypes (HPO): 14
• MANE Select transcript: NM_139162

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17920
Approved symbol	MIEF2
Name	mitochondrial elongation factor 2
Location	17p11.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC23130, MiD49, D3B
Ensembl gene	ENSG00000177427
Ensembl biotype	protein_coding
OMIM	615498
Entrez	125170

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 15 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000323019, ENST00000395703, ENST00000395704, ENST00000395706, ENST00000577216, ENST00000578174, ENST00000578621, ENST00000579341, ENST00000583745, ENST00000902907, ENST00000902908, ENST00000902909, ENST00000902910, ENST00000902911, ENST00000935240, ENST00000955407, ENST00000955408

RefSeq mRNA: 3 — MANE Select: NM_139162 NM_001144900, NM_139162, NM_148886

CCDS: CCDS11193, CCDS45624, CCDS45625

Canonical transcript exons

ENST00000323019 — 4 exons

Exon	Start	End
ENSE00002698263	18263710	18266552
ENSE00002713318	18260662	18260737
ENSE00002749672	18263086	18263248
ENSE00003634008	18262714	18262867

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 89.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.3506 / max 33.9493, expressed in 1684 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159807	5.3506	1684

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
hindlimb stylopod muscle	UBERON:0004252	89.60	gold quality
apex of heart	UBERON:0002098	89.06	gold quality
muscle of leg	UBERON:0001383	86.98	gold quality
gastrocnemius	UBERON:0001388	86.67	gold quality
heart left ventricle	UBERON:0002084	86.26	gold quality
skeletal muscle tissue	UBERON:0001134	86.07	gold quality
lower esophagus mucosa	UBERON:0035834	85.73	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.61	gold quality
metanephros cortex	UBERON:0010533	83.11	gold quality
muscle tissue	UBERON:0002385	83.07	gold quality
heart	UBERON:0000948	82.90	gold quality
prefrontal cortex	UBERON:0000451	81.95	gold quality
adult mammalian kidney	UBERON:0000082	81.75	gold quality
cortical plate	UBERON:0005343	81.38	gold quality
left adrenal gland	UBERON:0001234	81.15	gold quality
right adrenal gland	UBERON:0001233	81.10	gold quality
right adrenal gland cortex	UBERON:0035827	81.05	gold quality
right atrium auricular region	UBERON:0006631	80.79	gold quality
esophagus mucosa	UBERON:0002469	80.56	gold quality
frontal cortex	UBERON:0001870	80.53	gold quality
left adrenal gland cortex	UBERON:0035825	80.52	gold quality
right uterine tube	UBERON:0001302	80.47	gold quality
saliva-secreting gland	UBERON:0001044	79.99	gold quality
kidney	UBERON:0002113	79.96	gold quality
cortex of kidney	UBERON:0001225	79.95	gold quality
pituitary gland	UBERON:0000007	79.84	gold quality
minor salivary gland	UBERON:0001830	79.84	gold quality
cerebellum	UBERON:0002037	79.77	gold quality
adenohypophysis	UBERON:0002196	79.76	gold quality
adrenal gland	UBERON:0002369	79.75	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.90

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

59 targeting MIEF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-3128	99.50	67.85	1258
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-940	99.37	66.14	2064

Literature-anchored findings (GeneRIF, showing 17)

• Smith-Magenis syndrome is caused by a de novo deletion on chromosome 17. (PMID:15517828)
• MiD49/51 are new mediators of mitochondrial division affecting Drp1 action at mitochondria. (PMID:21508961)
• Mitochondrial outer membrane protein that recruits fission mediator Drp1 to the mitochondrial surface. (PMID:21508961)
• we find that either MiD49 or MiD51 can mediate Drp1 recruitment and mitochondrial fission in the absence of Fis1 and Mff. (PMID:23283981)
• MIEF1 and MIEF2 are differentially expressed in human tissues during development (PMID:23880462)
• MiD49 and MiD51 can act independently of Mff and Fis1 in Drp1 recruitment and suggest that they provide specificity to the division of mitochondria. (PMID:23921378)
• These findings and data showing MARCH5-dependent degradation of MiD49 upon stress support the possibility that MARCH5 regulation of MiD49 is a novel mechanism controlling mitochondrial fission and, consequently, the cellular response to stress. (PMID:26564796)
• The results indicate that Drp1-dependent mitochondrial fission through MiD49/MiD51 regulates cristae remodeling during intrinsic apoptosis. (PMID:26903540)
• MiD49 and MiD51 recruit inactive forms of Drp1 in mitochondrial fission. [review] (PMID:27660309)
• Knockdown of MIEF2 reduces DOX-induced mitochondrial fission and apoptosis in cardiomyocytes and in vivo. Also, knockdown of MIEF2 protects heart from DOX-induced cardiotoxicity. Our study identifies a novel pathway composed of Foxo3a and MIEF2 that mediates DOX cardiotoxicity. (PMID:28137654)
• In health, MiD49 regulate Drp1-mediated fission, whereas in disease, epigenetic upregulation of MiD49 increases mitotic fission, which drives pathological proliferation and apoptosis resistance (PMID:29431643)
• cryo-electron microscopy structure of full-length human DRP1 co-assembled with MID49 and an analysis of structure- and disease-based mutations (PMID:29899447)
• An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: Diagnostic and therapeutic implications. (PMID:32068312)
• Mitochondrial fragmentation enables localized signaling required for cell repair. (PMID:32236517)
• MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer. (PMID:33317572)
• MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway. (PMID:33414447)
• Fatty acyl-coenzyme A activates mitochondrial division through oligomerization of MiD49 and MiD51. (PMID:38594588)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mief2	ENSDARG00000002377
mus_musculus	Mief2	ENSMUSG00000018599
rattus_norvegicus	Mief2	ENSRNOG00000028208

Paralogs (1): MIEF1 (ENSG00000100335)

Protein

Protein identifiers

Mitochondrial dynamics protein MID49 — Q96C03 (reviewed: Q96C03)

Alternative names: Mitochondrial dynamics protein of 49 kDa, Mitochondrial elongation factor 2, Smith-Magenis syndrome chromosomal region candidate gene 7 protein

All UniProt accessions (5): A8MT25, J3KTJ4, J3QR30, K7EKV6, Q96C03

UniProt curated annotations — full annotation on UniProt →

Function. Mitochondrial outer membrane protein involved in the regulation of mitochondrial organization. It is required for mitochondrial fission and promotes the recruitment and association of the fission mediator dynamin-related protein 1 (DNM1L) to the mitochondrial surface independently of the mitochondrial fission FIS1 and MFF proteins. Regulates DNM1L GTPase activity.

Subunit / interactions. Interacts with DNM1L.

Subcellular location. Mitochondrion outer membrane.

Tissue specificity. Expressed in all tissues tested with highest expression in heart and skeletal muscle.

Disease relevance. Combined oxidative phosphorylation deficiency 49 (COXPD49) [MIM:619024] An autosomal recessive, mitochondrial myopathy characterized by progressive muscle weakness, intermittent muscle pain, exercise intolerance, elevated serum creatine kinase, and deficiencies of multiple respiratory chain enzymes. The disease may be caused by variants affecting the gene represented in this entry.

Miscellaneous. Does not bind ADP or other nucleotides, in contrast to MIEF1.

Similarity. Belongs to the MID49/MID51 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96C03-1	1	yes
Q96C03-2	2
Q96C03-3	3

RefSeq proteins (3): NP_001138372, NP_631901, NP_683684 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR024810	MAB21L/cGLR	Family
IPR045909	MID49/MID51	Family
IPR046906	Mab-21_HhH/H2TH-like	Domain
IPR049097	MID51-like_C	Domain

Pfam: PF20266, PF21297

UniProt features (15 total): sequence variant 3, splice variant 3, topological domain 2, chain 1, mutagenesis site 1, sequence conflict 1, transmembrane region 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5WP9	ELECTRON MICROSCOPY	4.22

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96C03-F1	76.65	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 13

Mutagenesis-validated functional residues (1):

Position	Phenotype
235	unable to associate with dnm1l into filaments forming the tubular structures that wrap around the scission site.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 134 (showing top): GOBP_POSITIVE_REGULATION_OF_MITOCHONDRIAL_FISSION, GOBP_PROTEIN_TARGETING, MEF2_02, GOBP_REGULATION_OF_PROTEIN_TARGETING_TO_MEMBRANE, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, CACCAGC_MIR138, EFC_Q6, GOBP_REGULATION_OF_MITOCHONDRION_ORGANIZATION, GOBP_PROTEIN_TARGETING_TO_MEMBRANE, MODULE_205, GOBP_ORGANELLE_FISSION, GOBP_MITOCHONDRIAL_FISSION, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, GOBP_REGULATION_OF_MITOCHONDRIAL_FISSION, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE

GO Biological Process (4): mitochondrion organization (GO:0007005), regulation of mitochondrion organization (GO:0010821), positive regulation of mitochondrial fission (GO:0090141), positive regulation of protein targeting to membrane (GO:0090314)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial outer membrane (GO:0005741), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
organelle organization	1
mitochondrion organization	1
regulation of organelle organization	1
mitochondrial fission	1
positive regulation of organelle organization	1
positive regulation of developmental process	1
regulation of mitochondrial fission	1
protein targeting to membrane	1
positive regulation of cellular process	1
regulation of protein targeting to membrane	1
positive regulation of establishment of protein localization	1
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
mitochondrial membrane	1
organelle outer membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

630 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MIEF2	DNM1L	O00429	997
MIEF2	DENR	O43583	988
MIEF2	MFF	Q9GZY8	981
MIEF2	FIS1	Q9Y3D6	924
MIEF2	GFM2	Q969S9	890
MIEF2	GFM1	Q96RP9	810
MIEF2	MFN1	Q8IWA4	810
MIEF2	MFN2	O95140	795
MIEF2	MRRF	Q96E11	710
MIEF2	OPA1	O60313	685
MIEF2	MARCHF5	Q9NX47	663
MIEF2	TSFM	P43897	649
MIEF2	OMA1	Q96E52	643
MIEF2	DNM1	Q05193	643
MIEF2	TUFM	P49411	637

IntAct

23 interactions, top by confidence:

A	B	Type	Score
DNM1L	MIEF2	psi-mi:“MI:0915”(physical association)	0.700
DNM1L	MIEF2	psi-mi:“MI:0914”(association)	0.700
MIEF2	DNM1L	psi-mi:“MI:0403”(colocalization)	0.700
MIEF2	UBQLN1	psi-mi:“MI:0915”(physical association)	0.670
UBQLN1	MIEF2	psi-mi:“MI:0915”(physical association)	0.670
RABAC1	MIEF2	psi-mi:“MI:0915”(physical association)	0.620
AGTRAP	MIEF2	psi-mi:“MI:0915”(physical association)	0.560
UBQLN1	MIEF2	psi-mi:“MI:0915”(physical association)	0.560
MIEF2	AGTRAP	psi-mi:“MI:0915”(physical association)	0.560
NPTN	RTL8C	psi-mi:“MI:0914”(association)	0.350
SLC27A1	RIMOC1	psi-mi:“MI:0914”(association)	0.350
MIEF2	TOMM20	psi-mi:“MI:0403”(colocalization)	0.270
MIEF2	UBQLN4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (41): MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid), MIEF2 (Two-hybrid)

ESM2 similar proteins: A0JM23, A2ASA8, A2BID5, A4IG61, A7MB64, A8E4S7, B1WC10, B5DFG1, O00562, O00750, O08721, O08722, O46102, O76024, O95248, P0CI65, Q08AI8, Q14689, Q1LXZ7, Q3TNL8, Q567X9, Q5FVQ8, Q5NCS9, Q5RA76, Q5RBN0, Q5XIS8, Q66H52, Q6AZT7, Q6GNM3, Q6GPH6, Q6GQ81, Q6ZN44, Q6ZPE2, Q7TNH6, Q7Z494, Q8BGV8, Q8BWT5, Q8CEZ4, Q8CI17, Q8IWB1

Diamond homologs: A4IG61, Q5NCS9, Q5RA76, Q5RBN0, Q5XIS8, Q6GQ81, Q8BGV8, Q96C03, Q9NQG6, A7SFB5, A0A2B4RP11, A0A2B4RNI3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

130 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	103
Likely benign	23
Benign	1

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
1675695	GRCh37/hg19 17p11.2(chr17:16664739-20217378)x1	Pathogenic
638113	GRCh37/hg19 17p11.2(chr17:16908991-18322254)x1	Pathogenic
978475	NM_139162.4(MIEF2):c.241C>T (p.Gln81Ter)	Pathogenic

SpliceAI

965 predictions. Top by Δscore:

Variant	Effect	Δscore
17:18260733:CGCAG:C	donor_loss	1.0000
17:18260734:GCAGG:G	donor_loss	1.0000
17:18260735:CAG:C	donor_loss	1.0000
17:18260736:AGGTA:A	donor_loss	1.0000
17:18260737:GGT:G	donor_loss	1.0000
17:18260738:GTACA:G	donor_loss	1.0000
17:18260739:T:A	donor_loss	1.0000
17:18262711:CA:C	acceptor_loss	1.0000
17:18262712:A:AG	acceptor_gain	1.0000
17:18262712:A:G	acceptor_loss	1.0000
17:18262713:G:GA	acceptor_gain	1.0000
17:18262713:GGC:G	acceptor_gain	1.0000
17:18262713:GGCA:G	acceptor_gain	1.0000
17:18262864:GCGG:G	donor_gain	1.0000
17:18262866:GG:G	donor_gain	1.0000
17:18262866:GGGT:G	donor_loss	1.0000
17:18262867:GG:G	donor_gain	1.0000
17:18262867:GGTA:G	donor_loss	1.0000
17:18262868:G:GG	donor_gain	1.0000
17:18262869:T:A	donor_loss	1.0000
17:18263084:A:AG	acceptor_gain	1.0000
17:18263085:G:GG	acceptor_gain	1.0000
17:18263085:GT:G	acceptor_gain	1.0000
17:18263085:GTT:G	acceptor_gain	1.0000
17:18263085:GTTC:G	acceptor_gain	1.0000
17:18263085:GTTCA:G	acceptor_gain	1.0000
17:18263708:A:AG	acceptor_gain	1.0000
17:18263708:AGAAG:A	acceptor_gain	1.0000
17:18263709:G:GG	acceptor_gain	1.0000
17:18263709:GAA:G	acceptor_gain	1.0000

AlphaMissense

2878 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:18262848:C:A	A43D	0.992
17:18264018:T:A	W207R	0.989
17:18264018:T:C	W207R	0.989
17:18264117:T:A	W240R	0.989
17:18264117:T:C	W240R	0.989
17:18262833:C:A	A38D	0.988
17:18264387:T:A	W330R	0.986
17:18264387:T:C	W330R	0.986
17:18264201:T:A	W268R	0.983
17:18264201:T:C	W268R	0.983
17:18264080:G:C	R227S	0.980
17:18264080:G:T	R227S	0.980
17:18264203:G:C	W268C	0.979
17:18264203:G:T	W268C	0.979
17:18262864:G:C	K48N	0.978
17:18262864:G:T	K48N	0.978
17:18264111:A:C	S238R	0.978
17:18264113:C:A	S238R	0.978
17:18264113:C:G	S238R	0.978
17:18264079:G:C	R227T	0.976
17:18264020:G:C	W207C	0.972
17:18264020:G:T	W207C	0.972
17:18264120:G:C	D241H	0.970
17:18262830:C:A	A37D	0.968
17:18262857:C:A	A46D	0.968
17:18264121:A:T	D241V	0.965
17:18264079:G:T	R227M	0.964
17:18262800:A:T	N27I	0.963
17:18264389:G:C	W330C	0.962
17:18264389:G:T	W330C	0.962

dbSNP variants (sampled 300 via entrez): RS1000870724 (17:18259207 G>A), RS1001554029 (17:18263553 G>A), RS1001668062 (17:18262339 T>G), RS1001989308 (17:18266634 C>T), RS1001998606 (17:18261012 G>C), RS1002490480 (17:18263315 C>A,T), RS1002614501 (17:18259290 T>C), RS1002666807 (17:18259591 C>A), RS1003616652 (17:18260577 G>A,T), RS1003672872 (17:18260094 G>A), RS1003808870 (17:18260327 A>G), RS1004433611 (17:18262551 G>A), RS1004655041 (17:18260022 G>A), RS1005025392 (17:18264838 A>G), RS1005362433 (17:18263799 T>A,C,G)

Disease associations

OMIM: gene MIM:615498 | disease phenotypes: MIM:619024

GenCC curated gene-disease

Disease	Classification	Inheritance
combined oxidative phosphorylation deficiency 49	Limited	Unknown

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
mitochondrial disease	Limited	AR

Mondo (1): combined oxidative phosphorylation deficiency 49 (MONDO:0033569)

Orphanet (0):

HPO phenotypes

14 total (14 of 14 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0001288	Gait disturbance
HP:0003200	Ragged-red muscle fibers
HP:0003236	Elevated circulating creatine kinase concentration
HP:0003323	Progressive muscle weakness
HP:0003326	Myalgia
HP:0003546	Exercise intolerance
HP:0003551	Difficulty climbing stairs
HP:0003621	Juvenile onset
HP:0003688	Cytochrome C oxidase-negative muscle fibers
HP:0008314	Decreased activity of mitochondrial complex II
HP:0008347	Decreased activity of mitochondrial complex IV
HP:0011923	Decreased activity of mitochondrial complex I
HP:0011924	Decreased activity of mitochondrial complex III

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST008497_5	Change in neurofilament light levels	6.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

3 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs12603700	Efficacy	3	duloxetine	Major Depressive Disorder
rs3889402	Efficacy	3	duloxetine	Major Depressive Disorder
rs56355515	Efficacy	3	duloxetine	Major Depressive Disorder

PharmGKB variants

4 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs12603700	MIEF2	3	0.00	1	duloxetine
rs3889402	MIEF2	3	0.00	1	duloxetine
rs56355515	MIEF2	3	0.00	1	duloxetine
rs58042962	MIEF2	3	0.00	1	duloxetine

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Leflunomide	decreases expression	2
Valproic Acid	decreases expression, increases methylation	2
urushiol	decreases expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Deferoxamine	increases expression, affects cotreatment, decreases reaction	1
Diazinon	increases methylation	1
Glucose	affects cotreatment, increases expression, decreases reaction	1
Hydrogen Peroxide	affects expression	1
Melatonin	affects cotreatment, decreases reaction, increases expression	1
Smoke	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	decreases expression	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	affects expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_F1PW	HyCyte HeLa KO-hMIEF2	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.